Quantitate biotherapeutic drug-targets through Pharmacokinetic & pharmacodynamic

Share Article

With the success of Herceptin, biomarkers promises to transform drug discovery, clinical development and diagnostics in the R&D process. Join SMi Group in January 2013 London to discover the latest developments in compound screening and toxicity testing to companion diagnostic assays at our 6th annual Biomarkers Summit.

This year’s event will feature a wide variety of speakers and presentations, offering delegates the perfect opportunity to discuss new opportunities and strategies to accelerate go/no-go decision making in early and clinical development.

SMi is pleased to confirm Andrew Warren, Director, PK/PD/Immunogenicity Bioanalysis, Novartis as a speaker of the event.

He will discuss how to deliver safe starting and therapeutically relevant escalation doses for human studies, as well as target-mediated drug disposition and Assaying captured drug-target complexes. Attending will enable delegates to:

  • Accelerate companion diagnostics development for therapeutic indications
  • Validate and deliver biomarker for patient selection during clinical trials
  • Implement sub-grouping in patient segmentation studies
  • Utilise revised FDA regulatory guidelines to aid product development
  • Optimise reimbursement strategies for diagnostics
  • Maximise biomarker identification using epigenetic and metabolomic insights

For more information visit http://www.smi-online.co.uk/goto/biomarkers-summit62.asp alternatively contact Cem Tuna on +44 0 207 827 6736 or email on ctuna (at) smi-online (dot) co (dot) uk

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sonal Patel
SMi Group Ltd
0207 827 6106
Email >
Follow us on
Visit website